JAN 09, 2018 04:38 PM PST

Viruses could inspire nano drug-delivery device

Researchers have discovered a path toward virus-like, nanoscale devices that may be able to deliver drugs to cells by chipping away at a viral protein.

The protein is one of three that make up the protective shell, called the capsid, of natural adeno-associated viruses (AAV). By making progressively smaller versions of the protein, the researchers made capsids with unique abilities and learned a great deal about AAV’s mechanisms.

Bioengineer Junghae Suh, an associate professor of bioengineering at Rice University, studies the manipulation of nondisease-causing AAVs to deliver helpful cargo like chemotherapy drugs. Her research has led to the development of viruses that scientists can trigger with light or by extracellular proteases associated with certain diseases.

AAVs are small—about 25 nanometers—and contain a single strand of DNA inside tough capsids that consist of a mosaic of proteins known as VP1, VP2, and VP3.

AAVs have been used to deliver gene-therapy payloads, but nobody has figured out how AAV capsids physically reconfigure themselves when triggered by external stimuli, Suh says. That was the starting point for her lab.

‘Biocomputing nanoparticles’

“This virus has intrinsic peptide (small protein) domains hidden inside the capsid,” she says. “When the virus infects a cell, it senses the low pH and other endosomal factors, and these peptide domains pop out onto the surface of the virus capsid.

“This conformational change, which we termed an ‘activatable peptide display,’ is important for the virus because the externalized domains break down the endosomal membrane and allow the virus to escape into the cytoplasm,” Suh says. “In addition, nuclear localization sequences in those domains allow the virus to transit into the nucleus. We believed we could replace that functionality with something else.”

Suh and lead author Nicole Thadani, a graduate student at Rice, think their mutant AAVs can become “biocomputing nanoparticles” that detect and process environmental inputs and produce controllable outputs. Modifying the capsid is the first step.

Of the three natural capsid proteins, only VP1 and VP2 can be triggered to expose their functional peptides, but neither can make a capsid on its own. Shorter VP3s can form capsids by themselves, but do not display peptides. In natural AAVs, VP3 proteins outnumber each of their compadres 10-to-1.

That limits the number of peptides that can be exposed, so Suh, Thadani and their coauthors set out to change the ratio. That led them to truncate VP2 and synthesize mosaic capsids with VP3, resulting in successful alteration of the number of exposed peptides.

Never before seen in nature

Based on previous research, they inserted a common hexahistidine tag that made it easy to monitor the surface display of the peptide region.

“We wanted to boost the protein’s activable property beyond what occurs in the native virus capsid,” Thadani says. “Rather than displaying just five copies of the peptide per capsid, now we may be able to display 20 or 30 and get more of the bioactivity that we want.”

They then made a truncated VP2 able to form a capsid on its own. “The results were quite surprising, and not obvious to us,” Suh says.

“We chopped down that VP2 component enough to form what we call a homomeric capsid, where the entire capsid is made up of just that mutant subunit. That gave us viruses that appear to have peptide ‘brushes’ that are always on the surface,” says Suh.

“A viral structure like that has never been seen in nature,” she explains. “We got a particle with this peptide brush, with loose ends everywhere. Now we want to know if we can use these loose ends to attach other things or carry out other functions.”

Homomeric AAVs display as many as 60 peptides, while researchers could reprogram mosaic AAVs to respond to stimuli specific to particular cells or tissues and display a smaller desired number of peptides, they say.

“Viruses have evolved to invade cells very effectively,” Suh says. “We want to use our virus as a nanoparticle platform to deliver protein- or peptide-based therapeutics more efficiently into cells. We want to harness what nature has already created, tweak it a little bit, and use it for our purposes.”

 

This article was originally posted on futurity.org

About the Author
  • The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 2,700 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists-including two Nobel laureates-work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.
You May Also Like
OCT 09, 2018
Drug Discovery
OCT 09, 2018
Weight Loss Drug Reduces Incidence of Diabetes
A clinical trial weight loss drug, by the name of Lorcaserin—manufactured by Eisai Inc., was found to reduce the risk of diabetes by 19 percent in pa...
OCT 16, 2018
Neuroscience
OCT 16, 2018
Your brain tells if a placebo can treat pain
Placebo effect and predicting when a particular subject will have a placebo response by using as little as psychological questionnaires....
NOV 05, 2018
Microbiology
NOV 05, 2018
Potential Antidote to Botulism is Found
A microbe called Clostridium botulinum and sometimes two other strains of Clostridium bacteria can make a toxic chemical called botulism....
JAN 20, 2019
Drug Discovery
JAN 20, 2019
Combination Therapeutic Effective for Leishmaniasis and HIV Patients
In a study published in PLOS Neglected Diseases, a special combination therapy has been proven for efficacy in cases of coinfection with Visceral leishmani...
JAN 24, 2019
Drug Discovery
JAN 24, 2019
Why Do Promising Cancer Drugs Fail?
After almost 20 years of a once-promising cancer drugs known as MMP inhibitors suddenly failed in clinical trials, scientists are now eager to provide an e...
FEB 17, 2019
Drug Discovery
FEB 17, 2019
Drug Combination May Become Standard Treatment for Metastatic Kidney Cancer
Reporting from results of a phase 3 clinical trial, patients with metastatic kidney cancer may soon receive a new standard treatment involving a combinatio...
Loading Comments...